Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases.
Description | Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases. |
In vitro | Irsenontrine (E2027) is an orally administered compound that selectively inhibits phosphodiesterase 9 (PDE9), demonstrating targeted activity. |
In vivo | Irsenontrine, administered orally at doses of 0.3 and 3.3 mg/kg, significantly enhances novel object exploration in scopolamine-induced rats at the 3.3 mg/kg dose. Furthermore, the combined oral administration of Irsenontrine (1 mg/kg) and memantine hydrochloride (1 mg/kg) results in a significantly higher exploration percentage of a novel object compared to the administration of memantine hydrochloride (1 mg/kg) alone. |
Synonyms | E2027, Irsenontrine |
Molecular Weight | 390.443 |
Formula | C22H22N4O3 |
CAS No. | 1429509-82-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Irsenontrine 1429509-82-9 E2027 E 2027 E-2027 inhibitor inhibit